TUSTIN, CA--(Marketwired - November 26, 2013) -
| Highlighted Links |
|
|
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the following upcoming events.
Piper Jaffray 25th Annual Healthcare Conference
Date: Tuesday, December 3, 2013
Time: 4:00 PM Eastern Time
Location: The New York Palace Hotel, New York, New York
Presenter: Steven W. King, president and chief executive officer
Peregrine Pharmaceuticals Second Quarter Fiscal Year 2014 Financial Results
Date: Tuesday, December 10, 2013
Conference Call: 1:30 PM Pacific Time (4:30 PM Eastern Time)
(877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call
To listen to the live webcast of the Second Quarter Fiscal Year 2014 Financial Results, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
A replay of the Second Quarter Financial Results call will be available starting approximately two hours after its conclusion through December 17, 2013 by calling (855) 859-2056, or (404) 537-3406 and using passcode 17598749.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com
Digg this 
Bookmark with del.icio.us 
Add to Newsvine
Technorati: Peregrine Pharmaceuticals second quarter fiscal year 2014 bavituximab immunotherapy lung cancer
Help employers find you! Check out all the jobs and post your resume.
